Acrivon therapeutics reports fourth quarter and full year 2023 financial results and business highlights

Watertown, mass., march 28, 2024 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, acrivon predictive precision proteomics (ap3), today reported financial results for the fourth quarter and full year ended december 31, 2023 and provided business highlights.
ACRV Ratings Summary
ACRV Quant Ranking